International Journal of Inflammation, Cancer and Integrative Therapy
Open Access

Pancreatic cancer; Pancreaticoduodenectomy; Treatment; Pancreatic oncology; Chemotherapy

Introduction

The total 5-year survival rate is just 5%, making pancreatic cancer the tenth most often diagnosed disease and the fourth most prevalent cause of cancer mortality in the United States [1]. Only 20% of patients survive 5 years after undergoing total resection, chemotherapy, and radiation, highlighting the need for innovative therapeutics. 43000 instances of pancreatic cancer were reported in 2012, and as the population as a whole continues to age, this incidence is anticipated to rise [2,3].

The pancreas is a glandular organ located beneath the stomach that develops pancreatic cancer when cells start to grow uncontrollably and create a tumour. These malignant cells have the capacity to invade several bodily cavities [4]. There are several varieties of pancreatic cancer. About 90% of instances of pancreatic cancer are pancreatic adenocarcinomas, and occasionally the term "pancreatic cancer" is used to refer primarily to them. These adenocarcinomas develop in the pancreatic region that produces digesting enzymes. These cells can also give birth to a number of other cancers, which collectively constitute the maturation of the nonadenocarcinomas. The most common malignancy that results in death is pancreatic cancer. However, new developments have enhanced our capacity to care for individuals with this incredibly fatal condition. The key developments in the area are covered in this article, including advancements in chemotherapy regimens, imaging technologies, surgical technique, and our knowledge of the pathophysiology of pancreatic cancer.

Neuroendocrine excrescences, which develop from the pancreas' hormone-producing cells, account for around 1-2 of all occurrences of pancreatic cancer. When compared to pancreatic adenocarcinoma, they are often less aggressive. Unusual skin colour, back or abdominal pain, unexplained weight loss, light-colored faeces, dark urine, and appetite loss are all indications that you may have the most prevalent kind of pancreatic cancer [5]. Early phases of the complaint are often symptom-free, and symptoms precise enough to imply pancreatic cancer typically don't appear until the complaint has advanced [6, 7]. Pancreatic cancer typically spreads to other bodily areas by the time an opinion is formed [8]. More over half of occurrences of pancreatic adenocarcinoma occur in those over 70, while pancreatic cancer seldom strikes anyone under the age of 40. Among the risk factors for pancreatic cancer include smoking, rotundity, diabetes, and a few uncommon inheritable diseases. Five to ten instances are related to inherited genes [6, 9], while around 25 cases are related to smoking. Blood tests, vivisection, and a combination of medical imaging techniques like ultrasound or computed tomography are often used to identify pancreatic cancer [10]. Stages I through IV of the complaint are labelled, from early to late. The overall population has not been successfully screened [11]. Nonsmokers, those who keep a healthy weight and restrict their consumption of red or recycled meat, and those who do not smoke have a decreased risk of getting pancreatic cancer [12]. If a smoker quits, their chances of acquiring the complaint decrease, and after 20 attempts, they almost reach those of the general population.

Surgery, radiation, chemotherapy, palliative care, or a mix of these can all be used to treat pancreatic cancer. Options for treatment are only loosely based on the stage of cancer. Pancreatic adenocarcinoma can only be cured via surgery, which can also be used to improve quality of life without the possibility of a cure [5,11]. On occasion, a pain procedure and particular to improve digestion are required. Early palliative care is in fact advised for patients beginning curative treatment. Encyclopedia-wide, mortality from pancreatic malignancies of all varieties increased in 2015. In the United Kingdom and the United States, pancreatic cancer ranks third and fifth, respectively, in terms of cancer-related deaths. About 70 of the new cases in 2012 originated in the developed world, where the complaint is most prevalent. The prognosis for pancreatic adenocarcinoma is often quite bad; according to opinion, 25 individuals survive just once and 5 live for five times [13]. The five-year survival rate for malignancies that were previously diagnosed increases to roughly 20 percent. Better concerns pertain to neuroendocrine malignancies; five times the average estimate, 65 of those identified are still alive, while longevity varies greatly depending on the type of excrescence.

For metastatic pancreatic cancer, few effective chemotherapeutic treatments are available. Gemcitabine has been the preferred drug since the 1990s, and although many other drugs have been tested either alone or in combination with it, very few have shown to improve patients' chances of survival when they have advanced cancer.

The use of this regimen in the neoadjuvant context for patients with locally advanced or marginally resectable illness is starting to show promising results. A 33% R0 resection rate was attained (55% borderline resectable, 10% locally unresectable) in a recent trial of 21 patients with either unresectable or borderline resectable pancreatic cancer who underwent neoadjuvant FOLFIRINOX, and 24% of patients showed a meaningful pathologic response [14]. Pancreatic cancer care often involves surgery, and several improvements in surgical practise patterns and surgical skill have led to decreased perioperative morbidity and mortality. The risk of death in high volume facilities is today as low as 3% as a result of the centralization of pancreaticoduodenectomy, for instance, to higher-volume hospitals with higher-volume surgeons [15]. Pancreatic tumours were once thought to be either resectable or unresectable. Pancreatic cancer was given the "borderline resectable" designation by the National Comprehensive Cancer Network in 2003, which designates tumours that are connected with surrounding structures but are neither obviously resectable nor plainly unresectable. Neoadjuvant chemotherapy given to this group of patients aggressively has made surgery possible and may have increased survival in certain individuals. In a thorough assessment of the literature, it was also shown that vascular restoration following pancreaticoduodenectomy is safe. In addition to more involved open operations, laparoscopic procedures are being used more often to treat pancreatic cancer. Early research indicates that minimally invasive procedures may be successfully carried out, allowing for a quicker return to prior activity levels, a shorter hospital stay, and a faster recovery period following surgery [16]. Laparoscopic distal pancreatectomy has become a routine treatment for benign and malignant tumours of the pancreatic body and tail as a result of developing technology and expertise. In a multicenter trial, individuals with pancreatic ductal adenocarcinoma had either an open or laparoscopic distal pancreatectomy.

The use of laparoscopy for pancreaticoduodenectomy has been expanded, and several case studies have shown that it is more practical, safe, and effective than open surgery. Pancreatic surgery is also increasingly using the robotic platform. With this method, laparoscopy's drawbacks two-dimensional imaging, a lack of dexterity, and poor ergonomics are overcome. Zureikat et al. found a 90- day Clavien grade III-IV complication rate of 23% and an overall pancreatic fistula rate of 27% in a group of 30 patients having robotassisted major pancreatectomy and reconstruction. They came to the conclusion that safe robot-assisted surgery may be conducted with postoperative complication rates equivalent to open pancreatectomy. To precisely identify possible advantages and explicate long-term oncologic outcomes of minimally invasive pancreaticoduodenectomy, more experience and bigger, controlled research are required.

Advanced genetic understanding: Pancreatic cancer is caused by a variety of genetic changes, including germ line and somatic mutations. According to recent research, pancreatic cancer cells often harbour 63 genetic alterations, which may be categorized into twelve major signalling pathways. The k-ras oncogene, which is mutated in 20%– 30% of all human malignancies, is present in over 90% of pancreatic cancers. Codons 61 and 13 are occasionally affected by mutations in this oncogene, although exon 1 of codon 12 is where they most frequently occur. The PI3K-AKT pathway, which is involved in a number of crucial cellular processes, including survival and proliferation, is one route that is upregulated by mutated k-ras. Other oncogenes associated with Notch signalling pathway and the Sonic hedgehog pathway are also responsible for pancreatic carcinogenesis.

Conclusion

The disease pancreatic cancer still has a significant mortality rate. When a patient is identified, their condition may already be advanced, making surgery impossible. In addition to enhancing our capacity to treat patients with metastatic cancer, recent developments in chemotherapeutic regimens have also demonstrated promising results in the neoadjuvant context. Early detection and vigorous treatment of possibly pre-malignant entities are now possible because to advancements in imaging technologies and a better knowledge of the aetiology of pancreatic cancer. Pancreaticoduodenectomy's perioperative morbidity and mortality have decreased as a result of the development of large volume facilities, the use of imaging technologies, and the accessibility of speciality services like interventional radiology. Furthermore, improvements in surgical technology are making it possible to execute these treatments less invasively while still establishing their safety and viability. Even with these improvements, there is still space for growth. Today's pancreatic oncologists must concentrate on deepening their understanding of the genetic and molecular mechanisms behind oncogenesis as well as the creation of more specialised, less harmful systemic treatments.

Acknowledgement

Not applicable.

Conflict of Interest

Author declares no conflict of interest.

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.

Indexed at, Google Scholar , Crossref

2. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.

Google Scholar , Crossref

3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer statistics, 2006.

Google Scholar

4. Kraemer KH, Coon HG, Petinga RA, Barrett SF, Rahe AE, et al. (1975) National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014, USA. Proc Natl Acad Sci India 72: 59-63.

Google Scholar , Crossref

5. Pishvaian MJ, Brody JR (2017) Therapeutic implications of molecular subtyping for pancreatic cancer. Oncology 31: 159-166.

Indexed at, Google Scholar

6. Engel KB, Vaught J, Moore HM (2014) National Cancer Institute Biospecimen Evidence-Based Practices, a novel approach to pre-analytical standardization. Biopreserv Biobank 12: 148-150.

Indexed at, Google Scholar , Crossref

7. Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 37: 1039-1049.

Indexed at, Google Scholar , Crossref

8. Bond-Smith G, Banga N, Hammond TM, Imber CJ (2012) Pancreatic adenocarcinoma. Bmj 16: 344.

Indexed at, Google Scholar , Crossref

9. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, et al. (2013) Recent progress in pancreatic cancer. CA: Cancer J Clin 63: 318-348.

Indexed at, Google Scholar , Crossref

10. Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388: 73-85.

Indexed at, Google Scholar , Crossref

11. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreatic cancer. Lancet 378: 607-620.

Google Scholar , Crossref

12. Wang H, Naghavi M, Allen C, Barber, RM, et al. (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388: 1459-1544.

Indexed at, Google Scholar , Crossref

13. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349: 241-252.

Indexed at, Google Scholar , Crossref

14. Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, et al. (2013) Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 108: 236-241.

Indexed at, Google Scholar , Crossref

15. Schmidt CM, Turrini O, Parikh P, House MG, Zyromski NJ, et al. (2010) Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience. Arch Surg 145: 634-640.

Indexed at, Google Scholar , Crossref

16. Kim SC, Park KT, Hwang JW, Shin HC, Lee SS, et al. (2008) Comparative analysis of clinical outcomes for laparoscopic distal pancreatic resection and open distal pancreatic resection at a single institution. Surg Endosc 22: 261-268.

Indexed at, Google Scholar , Crossref